Latest filing published 02 Apr 2013 for Anika Therapeutics, Inc., €161k.
Insider track record
No signal scores available.
Closed purchases
Based on 9 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +18.2%Entry US$5.00 · Close at T+365 US$5.91
- +62.4%Entry US$4.90 · Close at T+365 US$7.96
- -43.0%Entry US$8.11 · Close at T+365 US$4.62
- -45.6%Entry US$8.61 · Close at T+365 US$4.68
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Kevin W. Quinlan: trading record in brief
Kevin W. Quinlan discloses dealings in Anika Therapeutics, Inc. to SEC (Form 4). In total, 20 filings cover trades dated from 10 March 2008 to 27 March 2013.
In open-market terms, that means 9 purchases worth €41k on one side and 4 sales worth €653k on the other. Netting one side against the other leaves €612k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 5 share grants and 2 option exercises. In 2013 alone, the filings show no purchases and 4 sales.
A typical purchase (the median) is worth €4,090. Looking at 9 purchases old enough to measure, the stock rose over the following 90 days in 78% of cases; the median change was +13.4%. Past outcomes like these are no guarantee of what comes next.
The newest entry dates from 2 April 2013: an open-market sale of €161k, in Anika Therapeutics, Inc. The latest purchase dates back some time: it was published 5,921 days ago, on 24 August 2010. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Kevin W. Quinlan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 18,374 shares@ US$11.24Common StockSEC:0001140361-13-015029:0
- 25,000 shares@ US$11.24Common StockSEC:0001140361-13-013922:0
- 11,628 shares@ US$11.24Common StockSEC:0001140361-13-013922:2
- 19,998 shares@ US$11.24Common StockSEC:0001140361-13-013922:4
- 5,000 shares@ US$6.99Common StockSEC:0001140361-13-010486:0
- 6,368 shares@ US$6.99Common StockSEC:0001140361-13-010486:1
- 4,000 shares@ US$5.00Common StockSEC:0001140361-10-034761:0Canonical exit: 21 Nov 2010 (T+90)
- 6,744 shares0Common StockSEC:0001104659-09-021366:0
- 1,000 shares@ US$5.34Common StockSEC:0001104659-08-069631:0Canonical exit: 4 Feb 2009 (T+90)
- 1,000 shares@ US$5.20Common StockSEC:0001104659-08-069631:1Canonical exit: 5 Feb 2009 (T+90)
- 100 shares@ US$8.20Common StockSEC:0001157523-08-002362:0Canonical exit: 17 Jun 2008 (T+90)
- 200 shares@ US$8.28Common StockSEC:0001157523-08-002362:1Canonical exit: 17 Jun 2008 (T+90)
- 800 shares@ US$8.29Common StockSEC:0001157523-08-002362:2Canonical exit: 17 Jun 2008 (T+90)
- 900 shares@ US$8.30Common StockSEC:0001157523-08-002362:3Canonical exit: 17 Jun 2008 (T+90)
- 500 shares@ US$9.95Common StockSEC:0001104659-08-017096:0Canonical exit: 8 Jun 2008 (T+90)
- 500 shares@ US$9.80Common StockSEC:0001104659-08-017096:1Canonical exit: 8 Jun 2008 (T+90)
16 of 16 declarations
